

Hidde J. Haisma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9095080/publications.pdf>

Version: 2024-02-01

110
papers

6,041
citations

76294

40
h-index

74108

75
g-index

112
all docs

112
docs citations

112
times ranked

7769
citing authors

#	ARTICLE	IF	CITATIONS
1	Endosomal escape pathways for delivery of biologicals. <i>Journal of Controlled Release</i> , 2011, 151, 220-228.	4.8	1,278
2	Histone acetyl transferases as emerging drug targets. <i>Drug Discovery Today</i> , 2009, 14, 942-948.	3.2	283
3	Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. <i>Hepatology</i> , 2004, 39, 1563-1573.	3.6	207
4	Targeting of adenoviral vectors through a bispecific single-chain antibody. <i>Cancer Gene Therapy</i> , 2000, 7, 901-904.	2.2	145
5	Beta-Glucuronidase-Mediated Drug Release. <i>Current Pharmaceutical Design</i> , 2002, 8, 1391-1403.	0.9	138
6	Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. <i>Journal of Hepatology</i> , 2003, 39, 153-161.	1.8	128
7	Lymphangiogenic Growth Factor Responsiveness Is Modulated by Postnatal Lymphatic Vessel Maturation. <i>American Journal of Pathology</i> , 2006, 169, 708-718.	1.9	125
8	A Novel Strategy to Modify Adenovirus Tropism and Enhance Transgene Delivery to Activated Vascular Endothelial Cells In Vitro and In Vivo. <i>Human Gene Therapy</i> , 2004, 15, 433-443.	1.4	124
9	Histone acetyltransferases are crucial regulators in NF- κ B mediated inflammation. <i>Drug Discovery Today</i> , 2011, 16, 504-511.	3.2	113
10	6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 337-344.	2.6	112
11	HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF- κ B p65 transcriptional activity. <i>Biochemical Pharmacology</i> , 2016, 108, 58-74.	2.0	105
12	Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. <i>Gene Therapy</i> , 1999, 6, 1469-1474.	2.3	104
13	A monoclonal antibody- β -glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. <i>British Journal of Cancer</i> , 1992, 66, 474-478.	2.9	100
14	Production of highly pure no-carrier added ^{89}Zr for the labelling of antibodies with a positron emitter. <i>Applied Radiation and Isotopes</i> , 1994, 45, 1143-1147.	0.7	94
15	Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished. <i>Journal of Virology</i> , 2002, 76, 2753-2762.	1.5	88
16	Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. <i>Gene Therapy</i> , 2000, 7, 1940-1946.	2.3	85
17	Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. <i>Nucleic Acids Research</i> , 2003, 31, 6064-6078.	6.5	84
18	Scavenger Receptor A: A New Route for Adenovirus 5. <i>Molecular Pharmaceutics</i> , 2009, 6, 366-374.	2.3	76

#	ARTICLE	IF	CITATIONS
19	Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5826-5834.	1.4	75
20	Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. <i>Cancer Gene Therapy</i> , 2001, 8, 342-351.	2.2	71
21	Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. <i>Gene Therapy</i> , 2003, 10, 1982-1991.	2.3	71
22	A Novel Ex vivo Model System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity. <i>Clinical Cancer Research</i> , 2004, 10, 8697-8703.	3.2	71
23	Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. <i>Journal of General Virology</i> , 2008, 89, 1097-1105.	1.3	70
24	Novel anthracycline-spacer- 125 I-glucuronide, 125 I-glucoside, and 125 I-galactoside prodrugs for application in selective chemotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 1597-1610.	1.4	66
25	A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. <i>British Journal of Cancer</i> , 2001, 84, 550-557.	2.9	66
26	Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. <i>Journal of Immunology</i> , 2002, 169, 5322-5331.	0.4	66
27	Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule. <i>Clinical Cancer Research</i> , 2008, 14, 8169-8177.	3.2	61
28	Synthesis and biological activity of 125 I-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. <i>Bioorganic and Medicinal Chemistry</i> , 1997, 5, 405-414.	1.4	60
29	Adenovirus-Mediated Gene Transfer of Placental Growth Factor to Perivascular Tissue Induces Angiogenesis via Upregulation of the Expression of Endogenous Vascular Endothelial Growth Factor-A. <i>Human Gene Therapy</i> , 2005, 16, 1422-1428.	1.4	57
30	Characterization of novel anthracycline prodrugs activated by human 125 I-glucuronidase for use in antibody-directed enzyme prodrug therapy. <i>Biochemical Pharmacology</i> , 1996, 52, 455-463.	2.0	56
31	A facile method for the labeling of proteins with zirconium isotopes. <i>Nuclear Medicine and Biology</i> , 1996, 23, 439-448.	0.3	55
32	Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody 125 I-glucuronidase conjugate. <i>International Journal of Cancer</i> , 2001, 91, 550-554.	2.3	55
33	Engineering Zinc Finger Protein Transcription Factors: The Therapeutic Relevance of Switching Endogenous Gene Expression On or Off at Command. <i>Journal of Molecular Biology</i> , 2005, 354, 507-519.	2.0	55
34	Evaluation of tumor-specific promoter activities in melanoma. <i>Gene Therapy</i> , 2005, 12, 330-338.	2.3	51
35	Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 460-466.	1.4	48
36	Protein Transduction Domains and their Utility in Gene Therapy. <i>Current Gene Therapy</i> , 2003, 3, 486-494.	0.9	48

#	ARTICLE	IF	CITATIONS
37	A new application for liposomes in cancer therapy. <i>FEBS Letters</i> , 1993, 336, 485-490.	1.3	47
38	Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. <i>Journal of Gene Medicine</i> , 2002, 4, 510-516.	1.4	47
39	Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. <i>Journal of Controlled Release</i> , 2003, 87, 159-165.	4.8	42
40	Gene doping: an overview and current implications for athletes. <i>British Journal of Sports Medicine</i> , 2013, 47, 670-678.	3.1	40
41	Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. <i>Pharmaceutical Research</i> , 2003, 20, 423-428.	1.7	39
42	Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. <i>Gene Therapy</i> , 2002, 9, 256-262.	2.3	37
43	The effects of \hat{I}^3 -interferon combined with 5-fluorouracil or 5-fluoro-2 \hat{a} ϵ^2 -deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. <i>International Journal of Cancer</i> , 1991, 48, 749-756.	2.3	36
44	Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. <i>Pharmaceutical Research</i> , 1996, 13, 604-610.	1.7	36
45	Secreted and tumour targeted human carboxylesterase for activation of irinotecan. <i>British Journal of Cancer</i> , 2002, 87, 659-664.	2.9	35
46	Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4855-4861.	2.6	34
47	Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 343-348.	2.0	32
48	A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. <i>British Journal of Cancer</i> , 2002, 86, 811-818.	2.9	32
49	Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. <i>Gynecologic Oncology</i> , 2006, 100, 521-532.	0.6	32
50	Anex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. <i>Journal of Gene Medicine</i> , 2006, 8, 35-41.	1.4	31
51	The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. <i>British Journal of Cancer</i> , 1998, 78, 1600-1606.	2.9	30
52	Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7763-7778.	1.4	30
53	A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. <i>Biochemical Pharmacology</i> , 2004, 68, 2273-2281.	2.0	29
54	Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. <i>Molecular Therapy</i> , 2008, 16, 1919-1926.	3.7	29

#	ARTICLE	IF	CITATIONS
55	Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. <i>British Journal of Cancer</i> , 1996, 73, 457-464.	2.9	28
56	Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 94, 352-362.	0.6	28
57	A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. <i>Gene Therapy</i> , 2007, 14, 1695-1704.	2.3	27
58	Synthesis and Evaluation of [¹⁸ F]-FEAnGA as a PET Tracer for ¹²⁵ I-Glucuronidase Activity. <i>Bioconjugate Chemistry</i> , 2010, 21, 911-920.	1.8	27
59	A next-generation sequencing method for gene doping detection that distinguishes low levels of plasmid DNA against a background of genomic DNA. <i>Gene Therapy</i> , 2019, 26, 338-346.	2.3	27
60	¹²⁵ I-Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPT. <i>Tetrahedron Letters</i> , 1995, 36, 1701-1704.	0.7	26
61	Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. <i>Arthritis Research and Therapy</i> , 2006, 8, R32.	1.6	26
62	PDGF-Receptor ¹²⁵ I-Targeted Adenovirus Redirects Gene Transfer from Hepatocytes to Activated Stellate Cells. <i>Molecular Pharmaceutics</i> , 2008, 5, 399-406.	2.3	26
63	¹⁸ F-FEAnGA for PET of ¹²⁵ I-Glucuronidase Activity in Neuroinflammation. <i>Journal of Nuclear Medicine</i> , 2012, 53, 451-458.	2.8	26
64	Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. <i>Cancers</i> , 2021, 13, 1543.	1.7	25
65	Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. <i>British Journal of Cancer</i> , 2005, 92, 882-887.	2.9	23
66	Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. <i>Prostate</i> , 2005, 62, 253-259.	1.2	23
67	Localization and imaging of radiolabelled monoclonal antibody against squamous-cell carcinoma of the head and neck in tumor-bearing nude mice. <i>International Journal of Cancer</i> , 1989, 44, 534-538.	2.3	22
68	A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions. <i>Journal of Immunological Methods</i> , 2000, 237, 131-145.	0.6	22
69	Pharmacological Interventions for Improving Adenovirus Usage in Gene Therapy. <i>Molecular Pharmaceutics</i> , 2011, 8, 50-55.	2.3	22
70	Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 5027-5032.	1.4	22
71	D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling. <i>EBioMedicine</i> , 2021, 68, 103412.	2.7	22
72	Improved Characteristics of a Human ¹²⁵ I-Glucuronidase ¹²⁵ I Antibody Conjugate after Deglycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy. <i>Bioconjugate Chemistry</i> , 1996, 7, 606-611.	1.8	21

#	ARTICLE	IF	CITATIONS
73	Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. <i>Cancer Gene Therapy</i> , 2006, 13, 606-618.	2.2	21
74	Selective targeting of adenovirus to $\alpha_v\beta_3$ integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. <i>International Journal of Pharmaceutics</i> , 2010, 391, 155-161.	2.6	21
75	Antibody-Free Detection of Protein Tyrosine Nitration in Tissue Sections. <i>ChemBioChem</i> , 2011, 12, 2016-2020.	1.3	21
76	Polyinosinic Acid Blocks Adeno-Associated Virus Macrophage Endocytosis <i>In Vitro</i> and Enhances Adeno-Associated Virus Liver-Directed Gene Therapy <i>In Vivo</i> . <i>Human Gene Therapy</i> , 2013, 24, 807-813.	1.4	21
77	Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer. <i>International Journal of Cancer</i> , 1987, 40, 758-762.	2.3	20
78	An assay for the detection of human anti-murine immunoglobulins in the presence of CA125 antigen. <i>Journal of Immunological Methods</i> , 1988, 106, 1-6.	0.6	20
79	Cationic polymeric gene delivery of β -glucuronidase for doxorubicin prodrug therapy. <i>Journal of Gene Medicine</i> , 1999, 1, 407-414.	1.4	20
80	Specific localization of In-111-labeled monoclonal antibody versus 67-Ga-labeled immunoglobulin in mice bearing human breast carcinoma xenografts. <i>Cancer Immunology, Immunotherapy</i> , 1984, 17, 62-65.	2.0	19
81	Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 1817.	1.5	19
82	Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors. <i>American Journal of Obstetrics and Gynecology</i> , 1988, 159, 843-848.	0.7	18
83	Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. <i>Biochemical Pharmacology</i> , 1999, 57, 673-680.	2.0	18
84	CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. <i>Cancers</i> , 2019, 11, 455.	1.7	18
85	Synthesis and evaluation of novel daunomycin-phosphate-sulfate β -glucuronide and β -glucoside prodrugs for application in adept. <i>Biorganic and Medicinal Chemistry Letters</i> , 1995, 5, 2975-2980.	1.0	17
86	Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. <i>Advanced Drug Delivery Reviews</i> , 1997, 24, 225-231.	6.6	17
87	Cytosolic β -glycosidases for activation of glycoside prodrugs of daunorubicin. <i>Biochemical Pharmacology</i> , 2003, 65, 1875-1881.	2.0	16
88	Localization of radiolabelled F(ab \prime) $_2$ fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. <i>International Journal of Cancer</i> , 1988, 42, 368-372.	2.3	15
89	Pronounced Antitumor Efficacy by Extracellular Activation of a Doxorubicin-Glucuronide Prodrug After Adenoviral Vector-Mediated Expression of a Human Antibody-Enzyme Fusion Protein. <i>Human Gene Therapy</i> , 2004, 15, 229-238.	1.4	15
90	Targeted adenovirus mediated inhibition of NF- κ B-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. <i>Journal of Controlled Release</i> , 2013, 166, 57-65.	4.8	15

#	ARTICLE	IF	CITATIONS
91	A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 88-95.	1.1	15
92	Tumour localisation with 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1430-1436.	0.9	14
93	Induction of \hat{I}^2 -Glucuronidase Release by Cytostatic Agents in Small Tumors. <i>Molecular Pharmaceutics</i> , 2012, 9, 3277-3285.	2.3	14
94	Step into the Groove: Engineered Transcription Factors as Modulators of Gene Expression. <i>Advances in Genetics</i> , 2006, 56, 131-161.	0.8	12
95	Adenovirus retargeting to surface expressed antigens on oral mucosa. <i>Journal of Gene Medicine</i> , 2010, 12, 365-376.	1.4	12
96	Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 216-222.	2.2	11
97	The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. <i>Cancer Gene Therapy</i> , 2006, 13, 150-158.	2.2	11
98	In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O- \hat{I}^2 -D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging \hat{I}^2 -Glucuronidase Activity in a Tumor/Inflammation Rodent Model. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00029.	0.7	9
99	Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer. <i>International Journal of Cancer</i> , 1997, 71, 237-245.	2.3	7
100	Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter. <i>Journal of Controlled Release</i> , 2007, 117, 1-10.	4.8	7
101	In vivo evaluation of [18F]FEAnGA-Me: a PET tracer for imaging \hat{I}^2 -glucuronidase (\hat{I}^2 -GUS) activity in a tumor/inflammation rodent model. <i>Nuclear Medicine and Biology</i> , 2012, 39, 854-863.	0.3	7
102	Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein. <i>International Journal of Molecular Medicine</i> , 2007, 19, 841-9.	1.8	6
103	Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity. <i>Journal of Drug Targeting</i> , 2008, 16, 26-35.	2.1	4
104	Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens. <i>Journal of Immunological Methods</i> , 1992, 154, 55-60.	0.6	2
105	Tumor-specific activation of prodrugs: is there a role for nuclear medicine?. <i>Nuclear Medicine Communications</i> , 2008, 29, 845-846.	0.5	2
106	Higher ADCC of murine peritoneal cells after immunization with allogenic tumor cells as compared with stimulation by adriamycin, BCG, and thioglycolate. <i>Cellular Immunology</i> , 1986, 101, 454-462.	1.4	1
107	Transductional targeting of adenoviral vectors to prostate cancer in vitro. <i>Prostate Cancer and Prostatic Diseases</i> , 1999, 2, S5-S5.	2.0	1
108	153. VEGF Associated with TP To Refine Angiogenesis in Gene Therapy. <i>Molecular Therapy</i> , 2004, 9, S58-S59.	3.7	1

#	ARTICLE	IF	CITATIONS
109	Towards a double controlled conditionally replicative adenovirus for potent and specific melanoma cell kill. <i>Journal of Controlled Release</i> , 2006, 116, e64-e66.	4.8	0
110	Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. <i>Cancer Immunology, Immunotherapy</i> , 1995, 40, 24-30.	2.0	0